These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36843459)

  • 1. [Long-term Efficacy and Safety of Sampeginterferon-β1a in the Treatment of Relapsing Remitting Multiple Sclerosis: a Randomized, Double-Blind Clinical Trial 104-Week Results].
    Boyko AN; Bakhtiyarova KZ; Boyko OV; Dudin VA; Zaslavskii LG; Malkova NA; Parshina EV; Poverennova IY; Sivertseva SA; Totolyan NA; Shchur SG; Khabirov FA; Goncharova ZA; Zakharova MN; Bolsun DD; Zinkina-Orikhan AV; Lin'kova YN; Chernovskaya TV; Porozova AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(2):52-59. PubMed ID: 36843459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy and safety of sampeginterferon β-1a in the treatment of relapsing remitting multiple sclerosis: results of 52 weeks of therapy in a randomized, double-blind clinical trial].
    Boyko AN; Boyko OV; Bakhtiyarova KZ; Gusev EI; Dudin VA; Zaslavsky LG; Malkova NA; Parshina YV; Poverennova IY; Siverceva SA; Totolyan NA; Shchur SG; Fedulov AS; Khabirov FA; Bolsun DD; Zinkina-Orikhan AV; Linkova YN; Chernovskaya TV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(1):62-71. PubMed ID: 35175704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The new pegylated interferon beta-1a (sampeginterferon beta-1a, BCD-054) in the treatment of remitting multiple sclerosis].
    Boyko AN; Bakhtiyarova KZ; Dudin VA; Zaslavsky LG; Malkova NA; Parshina YV; Fedulov AS; Zinkina-Orikhan AV; Linkova YN; Ivanov RA; Chernovskaya TV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(10. Vyp. 2):100-109. PubMed ID: 31934995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and safety of intramuscular interferon beta-1a: Randomized postmarketing trial of two dosing regimens in Japanese patients with relapsing-remitting multiple sclerosis.
    Saida T; Kira J; Ueno Y; Harada N; Hirakata T
    Mult Scler Relat Disord; 2016 May; 7():102-8. PubMed ID: 27237769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-use autoinjector for peginterferon-β1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study.
    Seddighzadeh A; Hung S; Selmaj K; Cui Y; Liu S; Sperling B; Calabresi PA
    Expert Opin Drug Deliv; 2014 Nov; 11(11):1713-20. PubMed ID: 25073663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
    Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
    BMC Neurol; 2018 Sep; 18(1):143. PubMed ID: 30217172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
    Calabresi PA; Kieseier BC; Arnold DL; Balcer LJ; Boyko A; Pelletier J; Liu S; Zhu Y; Seddighzadeh A; Hung S; Deykin A;
    Lancet Neurol; 2014 Jul; 13(7):657-65. PubMed ID: 24794721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pegylated interferon beta 1a. A new therapy option for treatment of relapsing-remitting multiple sclerosis].
    Leussink VI; Warnke C; Tackenberg B; Wiendl H; Kieseier BC
    Nervenarzt; 2015 Apr; 86(4):483-90. PubMed ID: 25833401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing-Remitting Multiple Sclerosis.
    Orefice NS; Alhouayek M; Carotenuto A; Montella S; Barbato F; Comelli A; Calignano A; Muccioli GG; Orefice G
    Neurotherapeutics; 2016 Apr; 13(2):428-38. PubMed ID: 26857391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis.
    Zhang J; Shi S; Zhang Y; Luo J; Xiao Y; Meng L; Yang X
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD010968. PubMed ID: 29178444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
    Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
    Cohen JA; Comi G; Selmaj KW; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Kubala Havrdová E; Cree BAC; Sheffield JK; Minton N; Raghupathi K; Huang V; Kappos L;
    Lancet Neurol; 2019 Nov; 18(11):1021-1033. PubMed ID: 31492652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
    Comi G; Kappos L; Selmaj KW; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Kubala Havrdová E; Cree BAC; Sheffield JK; Minton N; Raghupathi K; Ding N; Cohen JA;
    Lancet Neurol; 2019 Nov; 18(11):1009-1020. PubMed ID: 31492651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis.
    Li DK; Paty DW
    Ann Neurol; 1999 Aug; 46(2):197-206. PubMed ID: 10443885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis.
    Agashivala N; Kim E
    Clin Ther; 2012 Jul; 34(7):1583-90. PubMed ID: 22749258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 years.
    Lublin FD; Cofield SS; Cutter GR; Gustafson T; Krieger S; Narayana PA; Nelson F; Salter AR; Wolinsky JS
    Mult Scler Relat Disord; 2017 Nov; 18():95-102. PubMed ID: 29141831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis.
    De Stefano N; Curtin F; Stubinski B; Blevins G; Drulovic J; Issard D; Shotekov P; Gasperini C;
    Mult Scler; 2010 Jul; 16(7):888-92. PubMed ID: 20200197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
    Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr KM; Søgaard LV; Olsen IC; Sandberg-Wollheim M
    Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis.
    Tolley K; Hutchinson M; You X; Wang P; Sperling B; Taneja A; Siddiqui MK; Kinter E
    PLoS One; 2015; 10(6):e0127960. PubMed ID: 26039748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis.
    Barkhof F; Kappos L; Wolinsky JS; Li DKB; Bar-Or A; Hartung HP; Belachew S; Han J; Julian L; Sauter A; Napieralski J; Koendgen H; Hauser SL
    Neurology; 2019 Nov; 93(19):e1778-e1786. PubMed ID: 31484710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.